Top ▲

5-HT1B receptor

Click here for help

Target id: 2

Nomenclature: 5-HT1B receptor

Family: 5-Hydroxytryptamine receptors

Gene and Protein Information Click here for help
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 390 6q14.1 HTR1B 5-hydroxytryptamine receptor 1B 19,19,25,47,57
Mouse 7 386 9 44.61 cM Htr1b 5-hydroxytryptamine (serotonin) receptor 1B 40
Rat 7 386 8q31 Htr1b 5-hydroxytryptamine receptor 1B 1,81
Previous and Unofficial Names Click here for help
5-HT1B | 5-HT1DB | HTR1D2 | 5-HT1B serotonin receptor | serotonin receptor 1B | 5-HT1Dβ [57,88] | 5-hydroxytryptamine (serotonin) receptor 1B, G protein-coupled
Database Links Click here for help
Specialist databases
GPCRDB 5ht1b_human (Hs), 5ht1b_mouse (Mm), 5ht1b_rat (Rn)
Other databases
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
Pharos
RefSeq Nucleotide
RefSeq Protein
UniProtKB
Wikipedia
Selected 3D Structures Click here for help
Image of receptor 3D structure from RCSB PDB
Description:  Crystal structure of the chimeric protein of 5-HT1B-BRIL in complex with dihydroergotamine
PDB Id:  4IAQ
Ligand:  dihydroergotamine
Resolution:  2.8Å
Species:  Human
References:  82
Image of receptor 3D structure from RCSB PDB
Description:  Crystal structure of the chimeric protein of 5-HT1B-BRIL in complex with ergotamine
PDB Id:  4IAR
Ligand:  ergotamine
Resolution:  2.7Å
Species:  Human
References:  82
Natural/Endogenous Ligands Click here for help
5-HT-moduline
5-hydroxytryptamine
tryptamine
Comments: Endogenous ligand tryptamine is a weak agonist

Download all structure-activity data for this target as a CSV file go icon to follow link

Agonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
[3H]N-methyl-AZ10419369 Small molecule or natural product Ligand is labelled Ligand is radioactive Hs Partial agonist 9.4 pKd 37
pKd 9.4 (Kd 3.7x10-10 M) [37]
[3H]8-OH-DPAT Small molecule or natural product Click here for species-specific activity table Ligand is labelled Ligand is radioactive Hs Full agonist 8.9 pKd 52
pKd 8.9 [52]
[125I]GTI Small molecule or natural product Click here for species-specific activity table Ligand is labelled Ligand is radioactive Rn Agonist 8.9 pKd 9-10
pKd 8.9 (Kd 1.3x10-9 M) [9-10]
[3H]alniditan Small molecule or natural product Click here for species-specific activity table Ligand is labelled Ligand is radioactive Hs Full agonist 8.6 – 9.0 pKd 32
pKd 8.6 – 9.0 (Kd 2.51x10-9 – 1x10-9 M) [32]
[3H]eletriptan Small molecule or natural product Click here for species-specific activity table Ligand is labelled Ligand is radioactive Hs Partial agonist 8.5 pKd 50
pKd 8.5 (Kd 3x10-9 M) [50]
[3H]sumatriptan Small molecule or natural product Click here for species-specific activity table Ligand is labelled Ligand is radioactive Hs Partial agonist 8.0 pKd 50
pKd 8.0 (Kd 1.1x10-8 M) [50]
5-hydroxytryptamine Small molecule or natural product Click here for species-specific activity table Ligand is endogenous in the given species Ligand has a PDB structure Hs Full agonist 7.5 – 8.4 pKd 55,88
pKd 7.5 – 8.4 [55,88]
donitriptan Small molecule or natural product Click here for species-specific activity table Rn Partial agonist 9.7 pKi 26
pKi 9.7 [26]
oxymetazoline Small molecule or natural product Approved drug Click here for species-specific activity table Hs Full agonist 9.5 pKi 30
pKi 9.5 [30]
GR 127935 Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 9.0 – 9.8 pKi 17,28,61,70,87
pKi 9.0 – 9.8 [17,28,61,70,87]
donitriptan Small molecule or natural product Click here for species-specific activity table Hs Full agonist 9.4 pKi 26
pKi 9.4 [26]
L-694,247 Small molecule or natural product Click here for species-specific activity table Hs Full agonist 9.2 pKi 18
pKi 9.2 (Ki 6.3x10-10 M) [18]
SB 216641 Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 9.0 pKi 61
pKi 9.0 [61]
alniditan Small molecule or natural product Click here for species-specific activity table Hs Full agonist 8.8 – 9.0 pKi 33
pKi 8.8 – 9.0 [33]
7-methoxy-1-naphthylpiperazine Small molecule or natural product Click here for species-specific activity table Hs Full agonist 8.7 pKi 28
pKi 8.7 [28]
CP94253 Small molecule or natural product Hs Full agonist 8.7 pKi 29
pKi 8.7 (Ki 2x10-9 M) [29]
dihydroergotamine Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Full agonist 8.0 – 9.2 pKi 33,55
pKi 8.0 – 9.2 [33,55]
CGS-12066 Small molecule or natural product Click here for species-specific activity table Hs Full agonist 8.1 – 8.7 pKi 18,88
pKi 8.1 – 8.7 [18,88]
ziprasidone Small molecule or natural product Approved drug Click here for species-specific activity table Hs Full agonist 8.3 pKi 69
pKi 8.3 [69]
5-CT Small molecule or natural product Click here for species-specific activity table Hs Full agonist 7.7 – 8.8 pKi 55,88
pKi 7.7 – 8.8 [55,88]
5-hydroxytryptamine Small molecule or natural product Click here for species-specific activity table Ligand is endogenous in the given species Ligand has a PDB structure Hs Full agonist 7.4 – 9.0 pKi 13,51-52,70,87-88
pKi 7.4 – 9.0 [13,51-52,70,87-88]
5-(nonyloxy)-tryptamine Small molecule or natural product Hs Full agonist 8.2 pKi 18
pKi 8.2 [18]
lysergol Small molecule or natural product Click here for species-specific activity table Hs Full agonist 7.5 – 8.9 pKi 55,88
pKi 7.5 – 8.9 [55,88]
5-CT Small molecule or natural product Click here for species-specific activity table Mm Full agonist 8.1 pKi 40
pKi 8.1 [40]
5-hydroxytryptamine Small molecule or natural product Click here for species-specific activity table Ligand is endogenous in the given species Ligand has a PDB structure Mm Full agonist 8.1 pKi 40
pKi 8.1 [40]
asenapine Small molecule or natural product Approved drug Click here for species-specific activity table Hs Full agonist 8.1 pKi 69
pKi 8.1 [69]
RU 24969 Small molecule or natural product Click here for species-specific activity table Hs Full agonist 8.1 pKi 40
pKi 8.1 [40]
naratriptan Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Partial agonist 8.1 pKi 50
pKi 8.1 [50]
eletriptan Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Full agonist 8.0 pKi 50
pKi 8.0 (Ki 1x10-8 M) [50]
frovatriptan Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Agonist 8.0 pKi 91
pKi 8.0 (Ki 1.03x10-8 M) [91]
BMS 181,101 Small molecule or natural product Hs Partial agonist 7.6 – 8.1 pKi 51
pKi 7.6 – 8.1 [51]
1-naphthylpiperazine Small molecule or natural product Click here for species-specific activity table Hs Full agonist 7.7 – 7.9 pKi 28,55,88
pKi 7.7 – 7.9 [28,55,88]
lisuride Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Partial agonist 7.7 pKi 44
pKi 7.7 [44]
zolmitriptan Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Partial agonist 7.7 pKi 50
pKi 7.7 [50]
avitriptan Small molecule or natural product Click here for species-specific activity table Hs Agonist 7.7 pKi 68
pKi 7.7 (Ki 2.09x10-8 M) [68]
vortioxetine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Immunopharmacology Ligand Hs Partial agonist 7.5 pKi 4
pKi 7.5 (Ki 3.3x10-8 M) [4]
avitriptan Small molecule or natural product Click here for species-specific activity table Rn Agonist 7.4 pKi 68
pKi 7.4 (Ki 3.63x10-8 M) [68]
5-MeOT Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Full agonist 7.3 – 7.5 pKi 55,88
pKi 7.3 – 7.5 [55,88]
dipropyl-5-CT Small molecule or natural product Click here for species-specific activity table Hs Full agonist 7.4 pKi 88
pKi 7.4 [88]
sumatriptan Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Partial agonist 6.5 – 8.1 pKi 18,33,45,50-51,55,88
pKi 6.5 – 8.1 (Ki 3.16x10-7 – 7.94x10-9 M) [18,33,45,50-51,55,88]
xanomeline Small molecule or natural product Click here for species-specific activity table Hs Full agonist 7.3 pKi 85
pKi 7.3 [85]
rizatriptan Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Partial agonist 6.9 pKi 50
pKi 6.9 [50]
L-775,606 Small molecule or natural product Hs Partial agonist 6.3 – 6.9 pKi 51
pKi 6.3 – 6.9 [51]
pergolide Small molecule or natural product Approved drug Click here for species-specific activity table Hs Full agonist 6.6 pKi 44
pKi 6.6 [44]
terguride Small molecule or natural product Approved drug Click here for species-specific activity table Hs Partial agonist 6.6 pKi 44
pKi 6.6 [44]
TFMPP Small molecule or natural product Click here for species-specific activity table Hs Full agonist 6.2 – 6.9 pKi 55,88
pKi 6.2 – 6.9 [55,88]
bromocriptine Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Partial agonist 6.5 pKi 44
pKi 6.5 [44]
LY344864 Small molecule or natural product Click here for species-specific activity table Hs Full agonist 6.3 pKi 58
pKi 6.3 [58]
cabergoline Small molecule or natural product Approved drug Click here for species-specific activity table Hs Full agonist 6.3 pKi 44
pKi 6.3 [44]
olanzapine Small molecule or natural product Approved drug Click here for species-specific activity table Hs Full agonist 6.3 pKi 69
pKi 6.3 [69]
tryptamine Small molecule or natural product Click here for species-specific activity table Ligand is endogenous in the given species Ligand has a PDB structure Hs Full agonist 6.3 pKi 88
pKi 6.3 [88]
clozapine Small molecule or natural product Approved drug Click here for species-specific activity table Hs Full agonist 6.2 pKi 69
pKi 6.2 [69]
BRL-15572 Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Partial agonist 6.1 pKi 61
pKi 6.1 [61]
aripiprazole Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Full agonist 6.1 pKi 72
pKi 6.1 [72]
2-methyl-5-HT Small molecule or natural product Click here for species-specific activity table Hs Full agonist 6.1 pKi 88
pKi 6.1 [88]
roxindole Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 5.8 – 6.0 pKi 44,52
pKi 5.8 – 6.0 [44,52]
capeserod Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 5.3 pKi 49
pKi 5.3 [49]
almotriptan Small molecule or natural product Approved drug Click here for species-specific activity table Hs Agonist 7.9 pIC50 8
pIC50 7.9 (IC50 1.2x10-8 M) [8]
Description: Affinity of almotriptan at recombinant h5-HT1B receptors expressed in HeLa cells, determined in a radioligand displacement assay using [125I]GTI as tracer.
CP-122288 Small molecule or natural product Click here for species-specific activity table Hs Full agonist 7.6 pIC50 15
pIC50 7.6 [15]
L-772,405 Small molecule or natural product Click here for species-specific activity table Hs Full agonist 6.8 pIC50 65
pIC50 6.8 [65]
8-OH-DPAT Small molecule or natural product Click here for species-specific activity table Hs Full agonist 6.2 pIC50 15
pIC50 6.2 [15]
[11C]AZ10419369 Small molecule or natural product Ligand is labelled Ligand is radioactive Hs Partial agonist - - 80
[80]
View species-specific agonist tables
Agonist Comments
Frovatriptan is selective for 1B and 1D 5-HT receptor subtypes compared to the 1A subtype [91].
BRL-15572 can be used to distinguish between 5-HT1D and 5-HT1B receptors, being approximately 60-fold selective for the 1D subtype [61].
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
GR-55562 Small molecule or natural product Hs Antagonist 7.4 pKB 23
pKB 7.4 [23]
[3H]GR 125,743 Small molecule or natural product Click here for species-specific activity table Ligand is labelled Ligand is radioactive Hs Antagonist 8.6 – 9.2 pKd 18,90
pKd 8.6 – 9.2 (Kd 2.6x10-9 – 7.1x10-10 M) [18,90]
GR 127935 Small molecule or natural product Click here for species-specific activity table Hs Antagonist 9.2 pKi 18
pKi 9.2 [18]
5-OH-DPAT Small molecule or natural product Mm Antagonist 8.4 pKi 40
pKi 8.4 [40]
SB 224289 Small molecule or natural product Click here for species-specific activity table Hs Inverse agonist 8.2 – 8.6 pKi 17,51,70
pKi 8.2 – 8.6 (Ki 6.31x10-9 – 2.51x10-9 M) [17,51,70]
ketanserin Small molecule or natural product Approved drug Click here for species-specific activity table Mm Antagonist 8.3 pKi 40
pKi 8.3 [40]
spiperone Small molecule or natural product Click here for species-specific activity table Mm Antagonist 8.3 pKi 40
pKi 8.3 [40]
yohimbine Small molecule or natural product Approved drug Click here for species-specific activity table Mm Antagonist 8.3 pKi 40
pKi 8.3 [40]
mianserin Small molecule or natural product Approved drug Click here for species-specific activity table Mm Antagonist 8.3 pKi 40
pKi 8.3 [40]
SB236057 Small molecule or natural product Hs Inverse agonist 8.2 pKi 42
pKi 8.2 (Ki 6.31x10-9 M) [42]
SB 272183 Small molecule or natural product Click here for species-specific activity table Hs Antagonist 8.1 pKi 86
pKi 8.1 [86]
(-)-pindolol Small molecule or natural product Mm Antagonist 8.1 pKi 40
pKi 8.1 [40]
cyanopindolol Small molecule or natural product Mm Antagonist 8.1 pKi 40
pKi 8.1 [40]
SB 649915 Small molecule or natural product Click here for species-specific activity table Hs Antagonist 8.0 pKi 84
pKi 8.0 [84]
methiothepin Small molecule or natural product Click here for species-specific activity table Hs Inverse agonist 7.1 – 8.5 pKi 18,51,55,87
pKi 7.1 – 8.5 [18,51,55,87]
GR-55562 Small molecule or natural product Hs Antagonist 7.5 pKi 18
pKi 7.5 [18]
yohimbine Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 6.8 – 7.6 pKi 45,88
pKi 6.8 – 7.6 [45,88]
zotepine Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 7.2 pKi 69
pKi 7.2 [69]
metergoline Small molecule or natural product Click here for species-specific activity table Hs Antagonist 7.2 pKi 55
pKi 7.2 [55]
methysergide Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 6.6 – 7.6 pKi 55,88
pKi 6.6 – 7.6 [55,88]
sertindole Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 7.0 pKi 69
pKi 7.0 [69]
risperidone Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 6.6 – 7.3 pKi 32,69,71
pKi 6.6 – 7.3 [32,69,71]
rauwolscine Small molecule or natural product Click here for species-specific activity table Hs Antagonist 6.5 – 7.4 pKi 55,88
pKi 6.5 – 7.4 [55,88]
9-OH-risperidone Small molecule or natural product Click here for species-specific activity table Hs Antagonist 6.8 pKi 69
pKi 6.8 [69]
SB 714786 Small molecule or natural product Click here for species-specific activity table Hs Antagonist 6.7 pKi 84
pKi 6.7 [84]
(S)-flurocarazolol Small molecule or natural product Click here for species-specific activity table Hs Antagonist 6.5 pKi 63
pKi 6.5 [63]
pipamperone Small molecule or natural product Click here for species-specific activity table Hs Antagonist 6.2 pKi 69
pKi 6.2 [69]
(R)-flurocarazolol Small molecule or natural product Click here for species-specific activity table Hs Antagonist 6.1 pKi 63
pKi 6.1 [63]
S33084 Small molecule or natural product Click here for species-specific activity table Hs Antagonist 6.1 pKi 43
pKi 6.1 [43]
(+)-WAY 100135 Small molecule or natural product Click here for species-specific activity table Hs Antagonist 5.8 pKi 13
pKi 5.8 [13]
ocaperidone Small molecule or natural product Click here for species-specific activity table Hs Antagonist 6.9 – 7.2 pIC50 32
pIC50 6.9 – 7.2 [32]
ritanserin Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 6.0 – 6.5 pIC50 15,32
pIC50 6.0 – 6.5 [15,32]
ketanserin Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 5.2 – 5.4 pIC50 15,32
pIC50 5.2 – 5.4 [15,32]
View species-specific antagonist tables
Antagonist Comments
It is possible that radioligand [3H]N-methyl-AZ10419369 may have properties as a partial agonist at the 5-HT1B receptor [37].
Allosteric Modulators
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
5-HT-moduline Peptide Click here for species-specific activity table Ligand is endogenous in the given species Hs Negative 11.9 pIC50 64
pIC50 11.9 [64]
Immunopharmacology Comments
The expression of 5-HT1B receptors on immune cells indicates that it plays some part in immune/inflammatory responses [83].
Cell Type Associations
Immuno Cell Type:  Granulocytes
Cell Ontology Term:   mature eosinophil (CL:0000041)
Comment:  Expressed by eosinophils.
References:  83
Immuno Cell Type:  Dendritic cells
Cell Ontology Term:   dendritic cell (CL:0000451)
Comment:  Involved in DC chemotaxis.
References:  2
Immuno Cell Type:  T cells
Comment:  Involved in T cell proliferation.
References:  2
Immuno Process Associations
Immuno Process:  Antigen presentation
GO Annotations:  Associated to 1 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0002031 G protein-coupled receptor internalization IEA
Primary Transduction Mechanisms Click here for help
Transducer Effector/Response
Gi/Go family Adenylate cyclase inhibition
References:  34,92
Tissue Distribution Click here for help
Benign and malignant prostate tissue.
Species:  Human
Technique:  Western blotting.
References:  14
Brain: substantia nigra, globus pallidus > striatum > amygdala, hippocampus, septa region, hypothalamus.
Species:  Human
Technique:  Radioligand binding.
References:  78
Trigeminal ganglion.
Species:  Human
Technique:  immunocytochemistry.
References:  22
Cortical cerebral arteries (smooth muscle cell layer > endothelial cell layer).
Species:  Human
Technique:  immunocytochemistry.
References:  53
Coronary artery > atrium > ventricle, epicardium.
Species:  Human
Technique:  RT-PCR.
References:  54
Brain: substantia nigra, globus pallidus > caudate nucleus, putamen, nucleus accumbens, central gray, hippocampal formation > various cortical regions.
Species:  Human
Technique:  Radioligand binding.
References:  7
Brain: striatum, cortex, lateral geniculate nucleus, raphe nucleus.
Species:  Human
Technique:  in situ hybridisation.
References:  79
Suprachiasmatic nucleus.
Species:  Mouse
Technique:  Electron microscopic immunocytochemistry.
References:  6,59
Hypothalamus: magnocellular nuclei > supraoptic nucleus, paraventricular nucleus (dorsolateral) and accessory perifornical, circular and retrochiasmatic nuclei.
Species:  Rat
Technique:  Immunohistochemistry.
References:  38
Lumbar dorsal root ganglia, superior cervical ganglia, lumbar sympathetic ganglia.
Species:  Rat
Technique:  RT-PCR.
References:  60
Suprachiasmatic nucleus.
Species:  Rat
Technique:  Radioligand binding.
References:  39
Trigeminal ganglion.
Species:  Rat
Technique:  Immunohistochemistry.
References:  36
Thymus, peripheral blood lymphocytes, spleen, mitogen-activated spleen cells.
Species:  Rat
Technique:  RT-PCR.
References:  76
CNS: ventral pallidum, globus pallidus, dorsal subiculum, substantia nigra > caudate–putamen, entopeduncular nucleus, superficial gray layer of the superior colliculus, deep nuclei of the cerebellum > cerebral cortex, thalamus.
Species:  Rat
Technique:  immunocytochemistry.
References:  66
Expression Datasets Click here for help

Show »

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays Click here for help
Measurement of cAMP levels in mouse adrenal Y-1 cells transfected with the 5-HT1B receptor.
Species:  Human
Tissue:  Y-1 cells.
Response measured:  Inhibition of cAMP accumulation.
References:  88
Measurement of cAMP levels in rat C6 glial cells transfected with the human 5-HT1B receptor.
Species:  Human
Tissue:  C6 glial cells.
Response measured:  Inhibition of cAMP accumulation.
References:  57
Measurement of cell growth ([3H]thymidine incorporation) of rat C6 glial cells transfected with the 5-HT1B receptor.
Species:  Human
Tissue:  C6 glial cells.
Response measured:  Cell proliferation.
References:  57
Measurement of cAMP levels in COS-7 cells transfected with the rat 5-HT1B receptor.
Species:  Rat
Tissue:  COS-7 cells.
Response measured:  Inhibition of cAMP accumulation.
References:  1
Measurement of cAMP levels in NIH3T3 cells endogenously expressing the 5-HT1B receptor.
Species:  Mouse
Tissue:  NIH3T3 cell line.
Response measured:  Inhibition of cAMP accumulation.
References:  40
Physiological Functions Click here for help
Vasoconstriction.
Species:  Human
Tissue:  Coronary artery.
References:  54
Vasocontriction.
Species:  Human
Tissue:  Cortical cerebral artery.
References:  53
Mediation of impulsivity and prefrontal cortex-dependent learning and memory.
Species:  Mouse
Tissue:  In vivo.
References:  56
Regulation of hippocampal functions.
Species:  Rat
Tissue:  In vivo.
References:  11
Inhibition of food intake.
Species:  Rat
Tissue:  In vivo.
References:  31
Presynaptic inhibition of GABA release onto GABAB receptors but not GABAA.
Species:  Rat
Tissue:  Dopamine-containing neurons of the midbrain.
References:  27
Inhibition of GABA release.
Species:  Rat
Tissue:  Globus pallidus.
References:  12
Relief from akinesia.
Species:  Rat
Tissue:  In vivo.
References:  12
Lowering of hippocampal excitatory synaptic transmission.
Species:  Rat
Tissue:  CA1 pyramidal neurons.
References:  46
Inhibition of glutamatergic synaptic transmission.
Species:  Rat
Tissue:  Hypoglossal motoneurons.
References:  74
Presynaptic inhibition of 5-HT (autoreceptor function), GABA and glutamate release (heteroreceptor function).
Species:  Mouse
Tissue:  Dorsal raphe, ventral midbrain and nucleus accumbens.
References:  48
Presynaptic decrease in retinal input to the circadian system.
Species:  Mouse
Tissue:  in vivo (retinal axons in the suprachiasmatic nucleus).
References:  59
Antinociception.
Species:  Mouse
Tissue:  Ventrolateral periaqueductal gray.
References:  5
Regulation of aggressive behaviour.
Species:  Mouse
Tissue:  In vivo.
References:  67
Presynaptic inhibition of 5-HT release.
Species:  Mouse
Tissue:  in vivo (frontal cortex and ventral hippocampus).
References:  77
Presynaptic inhibition of acetylcholine release.
Species:  Rat
Tissue:  Hippocampus.
References:  41
Presynaptic inhibition of dopamine release.
Species:  Rat
Tissue:  In vivo.
References:  3
Physiological Consequences of Altering Gene Expression Click here for help
5-HT1B receptor knockout mice exhibit elevated extracellular dopamine levels and dopamine release in the nucleus accumbens.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  73
5-HT1B receptor knockout mice exhibit altered decision making abilities and response inhibition.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  56
5-HT1B receptor knockout mice exhibit facilitated reference memory and impaired delay-dependent working memory.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  89
Juvenile 5-HT1B receptor knockout mice exhibit reduced anxiety and hyperactivity, reduced sensitivity to 5-HT1A receptor activity and reduced 5-HT1A receptor abundance in some brain regions.
Species:  Mouse
Tissue: 
Technique:  Transgenesis.
References:  16
5-HT1B receptor knockout mice lack inhibition of 5-HT, GABA and glutamate release in the CNS.
Species:  Mouse
Tissue: 
Technique:  Transgenesis.
References:  48
5-HT1B knockout mice exhibit a reduced effect of cocaine on the induction of the immediate-early gene c-fos, commonly used as a molecular marker for neuronal activation. Indicates that this receptor subtype is involved in mediating the stimulatory effects of cocaine.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  35
5-HT1B knockout mice exhibit increased aggressive behaviour.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  67
5-HT1B receptor knockout mice exhibit no inhibition of 5-HT release in the frontal cortex and ventral hippocampus.
Species:  Mouse
Tissue: 
Technique:  Transgenesis.
References:  77
5-HT1B knockout mice exhibit altered monoamine metabolism in the CNS.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  3
Phenotypes, Alleles and Disease Models Click here for help Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Htr1btm1Rhn|Slc6a4tm1Kpl Htr1btm1Rhn/Htr1btm1Rhn,Slc6a4tm1Kpl/Slc6a4tm1Kpl
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6
MGI:96274  MGI:96285  MP:0000285 abnormal heart valve morphology PMID: 16380550 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0003313 abnormal locomotor activation PMID: 12798274 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas * 129S6/SvEvTac
MGI:96274  MP:0002803 abnormal operant conditional behavior PMID: 12742250 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0005006 abnormal osteoblast physiology PMID: 19041748 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0000057 abnormal osteogenesis PMID: 19041748 
Htr1b+|Htr1btm1Rhn Htr1btm1Rhn/Htr1b+
involves: 129S2/SvPas
MGI:96274  MP:0000057 abnormal osteogenesis PMID: 19041748 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0001463 abnormal spatial learning PMID: 12798274 
Htr1btm1Rhn|Slc6a4tm1Kpl Htr1btm1Rhn/Htr1btm1Rhn,Slc6a4tm1Kpl/Slc6a4tm1Kpl
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6
MGI:96274  MGI:96285  MP:0003141 cardiac fibrosis PMID: 16380550 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0001364 decreased anxiety-related response PMID: 10996411 
Htr1btm1Rhn|Slc6a4tm1Kpl Htr1btm1Rhn/Htr1btm1Rhn,Slc6a4tm1Kpl/Slc6a4tm1Kpl
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6
MGI:96274  MGI:96285  MP:0005140 decreased cardiac muscle contractility PMID: 16380550 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0001489 decreased startle reflex PMID: 11164514 
Htr1btm1Rhn|Slc6a4tm1Kpl Htr1btm1Rhn/Htr1btm1Rhn,Slc6a4tm1Kpl/Slc6a4tm1Kpl
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6
MGI:96274  MGI:96285  MP:0002795 dilated cardiomyopathy PMID: 16380550 
Htr1btm1Rhn|Slc6a4tm1Kpl Htr1btm1Rhn/Htr1btm1Rhn,Slc6a4tm1Kpl/Slc6a4tm1Kpl
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6
MGI:96274  MGI:96285  MP:0003958 heart valve hyperplasia PMID: 16380550 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0001354 increased aggression towards males PMID: 8091214 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0001260 increased body weight PMID: 11164514  11790410 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0005605 increased bone mass PMID: 19041748